Status:
COMPLETED
Study Evaluating DVS-233 SR in Adult Outpatients With Major Depressive Disorder
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Depression
Depressive Disorder
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The main objective of this study is to compare the antidepressant efficacy and safety of DVS-233 SR versus placebo in adult outpatients with Major Depressive Disorder.
Eligibility Criteria
Inclusion
- Outpatients
- Men and women age 18 years of age and older
- Women of childbearing potential participating in the study must have a negative serum pregnancy test result at screening and use a medically acceptable form of contraception
Exclusion
- Treatment with DVS-233 SR at any time in the past
- Treatment with venlafaxine (immediate release \[IR\] or extended release \[ER\]) within 90 days of study day 1
- Known hypersensitivity to venlafaxine (IR or ER)
- Significant risk of suicide based on clinical judgment, including common
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2005
Estimated Enrollment :
244 Patients enrolled
Trial Details
Trial ID
NCT00092911
End Date
May 1 2005
Last Update
August 19 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.